Mirecule, Inc.
Publicly observedGaithersburg, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Gaithersburg | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Mirecule, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | D2DDKPAALJR3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant18 Sept 2024Publicly observed
NIH SBIR/STTR award: Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma
USD 896,878.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2021Publicly observed
NIH SBIR/STTR award: A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders
USD 608,751.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2021Publicly observed
NIH SBIR/STTR award: A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders
USD 1,225,173.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.